Elsevier

Brain Research

Volume 885, Issue 1, 1 December 2000, Pages 117-121
Brain Research

Short communication
Expression of CD40 in the brain of Alzheimer’s disease and other neurological diseases

https://doi.org/10.1016/S0006-8993(00)02984-XGet rights and content

Abstract

We have investigated immunohistochemically the expression of CD40 in post-mortem human brain tissues. In control brain, the blood vessels were stained weakly for CD40. Vascular expression of CD40 was enhanced in the lesions of Alzheimer’s disease and some other neurological diseases. In such diseases, reactive microglia were also positive for CD40. The results of this study suggest that CD40 expression by microglia is up-regulated upon a variety of brain insults and is not limited to lesions with amyloid β-protein deposits.

Section snippets

Acknowledgements

This research was supported by grants-in-aid from the Ministry of Education, Science and Culture of Japan (10670618).

References (18)

There are more references available in the full text version of this article.

Cited by (116)

  • Degree of genetic liability for Alzheimer's disease associated with specific proteomic profiles in cerebrospinal fluid

    2020, Neurobiology of Aging
    Citation Excerpt :

    These were enriched for cytokine-cytokine interactions. Cytokines play a major role in inflammatory and anti-inflammatory processes and are dysregulated in AD (Kauwe et al., 2014; Rubio-Perez and Morillas-Ruiz, 2012; Tarkowski et al., 2000; Togo et al., 2000; Zetterberg et al., 2004). The notion that these proteins were associated with PGRS that included the weakest SNPs suggests that many different SNPs may lead to inflammatory processes as observed in AD.

  • Molecular alterations in the medial temporal lobe in schizophrenia

    2020, Schizophrenia Research
    Citation Excerpt :

    On the other hand, microglial markers have also been reduced in a few studies either throughout the hippocampus (Morgan et al., 2016) or in specific subfields like CA1 or CA3 (Benes et al., 2007; Gos et al., 2014). Several studies have found no change in either number of microglia in hippocampus in individuals with schizophrenia (Steiner et al., 2006) or proinflammatory gene markers (Togo et al., 2000; Yokota et al., 2004) and cell types which exert immunological function (Arnold et al., 1996; Schmitt et al., 2009). In a meta-analysis of postmortem brain studies examining factors related to the immune system in individuals with schizophrenia and matched healthy controls, there was no significant change in overall expression of proinflammatory genes in the hippocampus (van Kesteren et al., 2017).

  • Blood-Brain Barrier: Genomics, Proteomics, Disease Targets, and Drug Delivery

    2017, Nanotechnology Methods for Neurological Diseases and Brain Tumors: Drug Delivery across the Blood-Brain Barrier
View all citing articles on Scopus
View full text